# Revance Therapeutics, Inc. — Form D

Revance Therapeutics, Inc. of NEWARK, CA, a company, filed a Form D exempt-offering notice with the SEC on 2013-02-22. The offering totals $60.0M, of which $5.0M was reported sold. Industry: Pharmaceuticals.

## Offering

- Filed: 2013-02-22
- Form: D
- Accession: 0001479290-13-000002
- Industry: Pharmaceuticals
- Exemptions: 06
- Total offering: $60.0M
- Amount sold: $5.0M
- Remaining: $55.0M
- Investors: 4
- Date of first sale: 2013-02-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-192272

## Issuer

- Name: Revance Therapeutics, Inc.
- CIK: 0001479290
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 7555 GATEWAY BLVD., NEWARK, CA, 94560
- Phone: 510-742-3400

## Officers, directors & promoters (19)

| Name | Role | Location |
| --- | --- | --- |
| L. Daniel Browne | Director | Newark, CA |
| Robert Daniel Byrnes | Director | Newark, CA |
| Ronald Daniel Eastman | Director | Newark, CA |
| Phyllis Daniel Gardner | Director | Newark, CA |
| Jim Daniel Glasheen | Director | Newark, CA |
| Frank Daniel Kung | Director | Newark, CA |
| Vicente Daniel Trelles | Director | Newark, CA |
| Jonathan Daniel Tunnicliffe | Director | Newark, CA |
| L. Daniel Browne | Executive Officer | Newark, CA |
| Ronald L Eastman | Director | Newark, CA |
| Frank L Kung | Director | Newark, CA |
| Phyllis L Gardner | Director | Newark, CA |
| Jonathan L Tunnicliffe | Director | Newark, CA |
| Daniel L Browne | Director | Newark, CA |
| Daniel L Browne | Executive Officer | Newark, CA |
| Vicente L Trelles | Director | Newark, CA |
| Robert L Byrnes | Director | Newark, CA |
| Jim L Glasheen | Director | Newark, CA |
| Ron Daniel Eastman | Director | Newark, CA |

## Other filings by this issuer (10)

| Filed | Form | Offering | Sold |
| --- | --- | --- | --- |
| [2013-10-23](https://search.stillhousedata.com/formd/0001479290-13-000003) | D | $30.0M | $10.0M |
| [2013-01-09](https://search.stillhousedata.com/formd/0001479290-13-000001) | D/A | $63.4M | $63.4M |
| [2012-09-14](https://search.stillhousedata.com/formd/0001479290-12-000002) | D/A | $50.9M | $50.9M |
| [2011-10-06](https://search.stillhousedata.com/formd/0001479290-11-000004) | D | $1.2M | — |
| [2011-06-14](https://search.stillhousedata.com/formd/0001479290-11-000003) | D/A | $45.0M | $45.0M |
| [2011-02-03](https://search.stillhousedata.com/formd/0001479290-11-000001) | D | $15.0M | $5.0M |
| [2010-11-18](https://search.stillhousedata.com/formd/0001479290-10-000003) | D/A | $36.2M | $36.2M |
| [2010-08-23](https://search.stillhousedata.com/formd/0001479290-10-000002) | D/A | $34.4M | $34.4M |
| [2010-06-01](https://search.stillhousedata.com/formd/0001479290-10-000001) | D/A | $33.4M | $33.4M |
| [2009-12-23](https://search.stillhousedata.com/formd/0001479290-09-000001) | D | $25.6M | $25.6M |

## More

- [CIK 1479290 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1479290&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001479290-13-000002.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.